Masimo Corporation (NASDAQ: MASI) has been downgraded from a “buy” rating to a “hold” rating by analysts at Wall Street Zen, as outlined in a research report released to clients on Saturday. This adjustment signals a shift in sentiment towards the company’s stock, which has recently seen a mix of ratings from various equities research analysts.
Several notable firms have provided updated perspectives on Masimo. On September 3, Zacks Research upgraded the company’s stock from “hold” to “strong-buy.” Meanwhile, on August 6, Piper Sandler increased their price target for Masimo from $200.00 to $210.00, assigning it an “overweight” rating. Additionally, BTIG Research reaffirmed a “buy” rating, setting a price target of $198.00 on September 11. Overall, one analyst has rated the stock as a strong buy, five have assigned a buy rating, and one has opted for a hold rating. According to data from MarketBeat, Masimo currently holds a consensus rating of “buy” with a price target averaging **$194.60**.
Latest Earnings and Performance
Masimo recently reported its financial results for the quarter ending August 5, 2023. The medical equipment provider achieved earnings of **$1.33** per share, surpassing analysts’ consensus estimate of **$1.22** by **$0.11**. The company recorded a revenue of **$370.90 million**, which also exceeded expectations of **$368.65 million**. This reflects a **7.7%** increase in revenue compared to the same quarter in the previous year when the company earned **$0.86** per share. Analysts predict an average of **4.1** earnings per share for the current fiscal year.
Despite the positive earnings report, Masimo reported a negative net margin of **24.85%**, alongside a positive return on equity of **26.54%**.
Insider Activity and Institutional Investments
In related news, Masimo’s Director, William R. Jellison, acquired **3,000** shares of the company on August 11 at an average price of **$145.98** per share, totaling **$437,940.00**. This purchase has increased his holdings to **4,790** shares, valued at **$699,244.20**, marking a **167.60%** increase in his position. This transaction has been officially reported to the Securities and Exchange Commission (SEC), where it can be reviewed.
Institutional ownership of Masimo remains high, with **85.96%** of the stock held by institutional investors and hedge funds. Recently, several firms have adjusted their stakes in the company. Twin Tree Management LP initiated a new position worth approximately **$29,000** in the first quarter, while MAI Capital Management expanded its position by **176.7%** during the second quarter, holding **202** shares worth **$34,000**. Farther Finance Advisors LLC also increased their stake by **128.9%**, now owning **206** shares valued at **$35,000**.
Masimo Corporation specializes in developing, manufacturing, and marketing patient monitoring technologies and connectivity solutions globally. Its innovative products include masimo signal extraction technology (SET) for pulse oximetry, which is designed to overcome the limitations of conventional monitoring methods. The company also offers a range of advanced monitoring solutions, including the rainbow SET platform, which provides noninvasive monitoring capabilities.
Overall, the recent downgrade by Wall Street Zen, alongside mixed ratings from other analysts, reflects the evolving outlook for Masimo as it navigates a competitive market while continuing to innovate in the medical technology space.
